Microsampling: what do we need to do to accelerate the real-life uptake?

Dried blood microsampling, originating in the newborn screening field, and also currently routinely applied in preclinical (animal) studies in the pharmaceutical industry, is increasingly receiving attention in the field of clinical chemistry. Many dried blood spot (DBS)-based methods have been developed for a variety of applications; for example, phenotyping, therapeutic drug monitoring, doping analysis and toxicology.

Despite the numerous advantages, there are several drawbacks and limitations for implementing dried blood microsampling in (clinical) routine. The past years have witnessed multiple methodological and technological developments that have helped to move the field forward; however, despite many advances, and despite a multitude of applications demonstrating the feasibility of dried blood microsampling for, e.g., therapeutic drug monitoring purposes, widespread implementation of dried blood microsampling in routine clinical care is still lagging behind.

This presentation will provide an overview of the distinct requirements for routine implementation of dried blood microsampling.

Of specific interested for people involved in clinical trials, epidemiological studies or longitudinal patient follow-up.
​​​​​​​

Your details

By submitting this form you are agreeing to our Terms & Conditions and Privacy Policy, and agree to receiving relevant emails from The Evidence Base about the latest news and editorial features.

Terms & Conditions

I agree to receive third party emails to keep me informed of relevant products and services relevant to my industry.

Subscribing to

Confirm sign-up

What you will learn:

Key advantages of dried blood microsampling
Key issues associated with dried blood microsampling
Key areas in which dried blood microsampling may be used
Key technological involvements during the past decade
How to correctly perform dried blood microsampling studies

Speaker:

Christophe Stove, PharmD, PhD
Associate Professor, Laboratory of Toxicology, Ghent University, Belgium

Christophe Stove, PharmD, PhD is Associate Professor at Ghent University, Belgium, where he heads the Laboratory of Toxicology at the Faculty of Pharmaceutical Sciences. Besides teaching some five courses (including toxicology, drug toxicity and bioanalysis), he directs the Lab’s service activities (forensic toxicology and reference laboratory activities) and steers the research, which covers applied cell biology and pharmacology, as well as bioanalysis. He has an extensive publication record (over 250 publications), with many publications in leading journals in the field, and serves as a corresponding author on the vast majority of these. He has an H-index of 48, has been cited over 7500 times (Google Scholar) and is currently Board/Council Member of 2 national (BLT, KBGGG) and 2 international (TIAFT and IATDMCT) associations.

Moderated by:

Neil Spooner
Director, Spooner Bioanalytical Solutions

Neil is the Founder of Spooner Bioanalytical Solutions, helping companies to integrate biological fluid microsampling, and patient centric sampling and analysis into workflows. He also works with organisations to develop technologies and introduce them to the market. Neil also assists organisations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire, Editor in Chief of the journal, Bioanalysis, Founder of the Patient Centric Sampling Interest Group and Co-Chair of the Reid Bioanalytical Forum. He has published over 70 peer reviewed manuscripts and delivered over 50 podium presentations.

Share this webinar